Mark Andrew White - Apr 4, 2023 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Role: Chief Medical Officer
Signature: /s/ Martin Wilson, as attorney-in-fact for Mark Andrew White
Stock symbol: RCKT
Transactions as of: Apr 4, 2023
Transactions value $: $0
Form type: 4
Date filed: 4/12/2023, 07:00 PM
Next filing: Feb 21, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RCKT	Common Stock, par value $0.01	Award	$0	+76.7K		$0.00	76.7K	Apr 4, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RCKT	Stock Option (Right to Buy)	Award	$0	+57.7K		$0.00	57.7K	Apr 4, 2023	Common Stock	57.7K	$17.41	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Holdings are Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on April 4, 2024, with the remaining shares vesting in equal quarterly installments over the following two years.
F2	This option represents a right to purchase a total of 57,739 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on April 4, 2024, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.